


Part II Organizational Action (continued)

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ▶ _____
Sections 354, 358 and 368 of the Internal Revenue Code.

18 Can any resulting loss be recognized? ▶ _____
See attachments.

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ▶ _____
See attachments.

Sign Here	Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.			
	Signature ▶ 	Date ▶ December 13, 2023		
Paid Preparer Use Only	Print your name ▶ Susan L. Drexler	Title ▶ Interim CFO		
	Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed PTIN
	Firm's name ▶	Firm's EIN ▶		
	Firm's address ▶	Phone no.		

Aileron Therapeutics, Inc., as successor to Lung Therapeutics, Inc.
EIN: 13-4196017
Attachment to Form 8937

Form 8937, Part II, Box 14:

On October 31, 2023, Aileron Therapeutics, Inc. (“Aileron”) acquired Lung Therapeutics, Inc. (“Lung”) through a two-step merger. In the first merger, a newly formed, wholly owned corporate subsidiary of Aileron merged with and into Lung, with Lung surviving the first merger and becoming a wholly owned subsidiary of Aileron. Immediately following the first merger and as part of the same overall transaction, Lung merged with and into a newly formed, wholly owned limited liability company subsidiary of Aileron, with that limited liability subsidiary surviving the second merger. Former Lung shareholders received shares of Aileron common stock and shares of Aileron non-voting, preferred convertible stock (“Series X Preferred Stock”) in exchange for their shares of Lung stock.

Each share of Series X Preferred Stock is convertible into 1,000 shares of Aileron common stock, subject to certain adjustments and conditions.

The first merger and the second merger, taken together, are intended to qualify as a reorganization under Section 368(a) of the Internal Revenue Code.

Form 8937, Part II, Box 15:

A shareholder's aggregate tax basis in shares of Aileron stock received (including any fractional shares deemed received and redeemed for cash as described below in Box 18) will equal the shareholder's tax basis in the Lung stock surrendered in exchange therefor. Treasury Regulations provide detailed rules for allocating the tax basis of the shares of Lung stock surrendered for the shares of Aileron stock received. If a shareholder acquired different blocks of Lung stock at different prices, the tax basis of each block of Aileron stock received by such holder in the merger will be determined on a block-for-block basis depending on the tax basis of the blocks of Lung stock surrendered in exchange therefor. Holders of shares of Lung stock should consult their tax advisors regarding the allocation of the tax basis of the holder's shares of Lung stock among the shares of Aileron stock received.

The above assumes that the mergers, taken together, qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.

Form 8937, Part II, Box 16:

See response to Box 15, above.

Form 8937, Part II, Box 18:

Generally, no. A shareholder may not recognize a loss, except with respect to cash received in lieu of a fractional share. Each shareholder will be treated as receiving such cash in redemption of its fractional share and gain or loss may be recognized on such redemption.

Form 8937, Part II, Box 19:

The reportable tax year is the taxable year of the shareholder in which the mergers occurred (e.g, 2023 for calendar-year taxpayers).